百心安-B(02185.HK):於EUROPCR開展RADIUS-HTN試驗
格隆匯5月19日丨百心安-B(02185.HK)宣佈,於EuroPCR 2022(為歐洲經皮心血管介入治療協會正式年會),公司與臨牀試驗研究員敲定計劃,涉及使用橈動脈入路的腎動脈去交感神經治療未控高血壓(RADIUS-HTN)的歐洲臨牀試驗("RADIUS-HTN試驗")。歐洲心血管研究中心("CERC")將進行RADIUS-HTN試驗,並評估公司的第二代Iberis®腎神經阻斷(RDN)系統治療未控高血壓患者。RADIUS-HTN試驗將比較通過經橈動脈入路(TRA)和經動脈入路(TFA)進行的腎神經阻斷的療效。RADIUS-HTN試驗的主要研究員為FelixMahfoud教授,來自Saarland University Hospital, Homburg/Saar的醫學士,亦為德國心臟病學會動脈高血壓工作小組主席。
公司為全球唯一一家擁有CE標誌可就TRA及TFA使用導管治療高血壓的公司。醫生及患者偏好使用TRA法進行血管介入治療。與TFA相比,TRA介入治療可減少侵入身體部位的併發症及縮短住院時間,同時降低手術成本及提高患者滿意度。第二代Iberis®是一種通過裝置進行用於治療高血壓的低侵入性手術。第二代Iberis®臨牀試驗乃與我們的戰略業務合作者泰爾茂合作開展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.